Danaher Co. (NYSE:DHR) Shares Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC increased its stake in Danaher Co. (NYSE:DHR) by 1.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 184,484 shares of the conglomerate’s stock after acquiring an additional 3,161 shares during the period. Janney Montgomery Scott LLC’s holdings in Danaher were worth $42,349,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new position in Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $55,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Up 0.6 %

Shares of NYSE:DHR opened at $245.73 on Friday. The company has a market cap of $177.49 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The firm’s 50-day simple moving average is $234.90 and its 200-day simple moving average is $253.47. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business posted $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, equities research analysts predict that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on DHR shares. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.